Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS, page-100

Whether we get into the top 100 would be a bonus but hardly an issue for shareholders who are holding for long term share price appreciation. After yesterday TLX is on everyone’s radar.

For me the focus is on short term catalysts that drive revenue. I would love to get an update in June with illuccix sales and forecast profit. Then I’ll be looking at cash flow from operations in the half yearly report. I do expect the illuccix franchise will be selling into Europe soon and finally at year end approval to sell the other imaging products in the states.

2025 is going to be a big year of revenue growth and de risking shareholder risk as revenue will be generated from multiple products in multiple jurisdictions. I actually believe in FY25 revenue will get to 2b . On a multiple of 8 to 9 times revenue I can see market cap around 18b aud or three times todays share price.
I am not assigning any value to the therapy pipeline either which would cause a material lift in price.

One thing is for certain, tlx will be in the asx 100 then lol